Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Endocrinology · Mitochondrial Diabetes

Endocrine Involvement: Mitochondrial Diabetes

At a Glance

Mitochondrial diabetes occurs when impaired mitochondrial energy production reduces insulin release, often in people who are lean and may have hearing loss or maternal family history. Treatment is individualized, and metformin requires careful medical review.

While many people are familiar with Type 1 and Type 2 diabetes, mitochondrial diabetes is a distinct condition with its own biological “rules.” It is frequently associated with a specific genetic change called the m.3243A>G mutation (though it is not the only cause), and it is often part of a syndrome known as MIDD (Maternally Inherited Diabetes and Deafness) [1][2].

In mitochondrial diabetes, the primary problem isn’t always your immune system (like Type 1) or just your body’s “resistance” to insulin (like Type 2), though insulin resistance can also occur. Instead, a major factor is an energy shortage. Your pancreas has specialized “beta cells” that act like sugar sensors. To release insulin, these cells must produce a burst of ATP (energy). If the mitochondria in these cells are dysfunctional, they can’t make enough ATP to trigger the release of insulin properly [3][1].

How It Differs from Other Types

Because the underlying cause is unique, mitochondrial diabetes looks different from other forms of the disease:

  • The “Lean” Phenotype: Unlike Type 2 diabetes, which is often associated with higher body weight, patients with mitochondrial diabetes are often lean or even underweight, though this is not a diagnostic rule by itself [4][5].
  • Hearing Loss: In some cohorts, a large percentage of people with MIDD also experience sensorineural hearing loss, which may occur before or after the diabetes diagnosis. Penetrance varies widely based on age and specific populations [4].
  • Maternal Inheritance: The condition is often passed down through the mother’s side of the family, though absence of this history does not rule it out [1].
  • Lack of Autoantibodies: Unlike Type 1 diabetes, blood tests for mitochondrial diabetes will usually be negative for the “autoantibodies” that signal an immune system attack [6].

Management and Medication Cautions

Managing mitochondrial diabetes requires a tailored approach because standard diabetes medications can sometimes interact poorly with mitochondrial disease. Never stop or restart medications, including Metformin, without your clinician’s instructions.

The Metformin Caution

Metformin is the most common first-line treatment for Type 2 diabetes, but it requires evaluation and caution in mitochondrial patients. Metformin works partly by affecting how mitochondria process energy, and it can increase the levels of lactic acid in your blood [7][8].

  • Lactic Acidosis Risk: The risk of lactic acidosis is driven especially by reduced kidney filtration (eGFR), acute kidney injury, hypoxia, sepsis, dehydration, or severe illness [9].
  • Kidney Concerns: Proximal tubular wasting with preserved eGFR (Fanconi syndrome) is not automatically the same as impaired Metformin clearance. However, because of the complex nature of mitochondrial disease, many experts recommend caution. Review your Metformin use with your doctor to determine if it remains safe for you [7].

Other Treatment Options

  • Insulin: Because the core problem often involves a failure to secrete insulin, many patients eventually require insulin therapy when endogenous secretion is inadequate for glycemic control [10][11].
  • Sulfonylureas: These medications can help the pancreas squeeze out more insulin, but carry a risk of hypoglycemia (dangerously low blood sugar) and may only work for a limited time [11].
  • Newer Therapies: Some early evidence suggests that newer classes of drugs, like GLP-1 receptor agonists (e.g., semaglutide), might be helpful for some patients as individualized options. However, they must be used carefully because they carry risks of weight loss, gastrointestinal adverse effects, and dehydration—particularly relevant to a patient who already has Fanconi syndrome [12][13].

Routine Diabetes Care and Monitoring

Routine diabetes care remains vital regardless of the genetic cause:

  1. Continuous Glucose Monitoring (CGM) and Sick Days: Knowing your individualized glucose targets is essential. You need practical instructions for recognizing and responding to both low and very high glucose, and knowing when to check for ketones during illness [14][15].
  2. Regular Hearing Checks: Since hearing loss is so closely linked, annual audiology exams are recommended [16].
  3. Comprehensive Checks: You need regular eye and foot care, blood-pressure and lipid assessments, and ongoing renal monitoring [17].
  4. Sick-Day Plan: When you are ill, your mitochondria are under extra stress. You should have a clear “sick-day plan” from your doctor to manage your insulin and hydration [18].

Common questions in this guide

What is mitochondrial diabetes, and how is it different from type 1 or type 2 diabetes?
Mitochondrial diabetes occurs when mitochondrial dysfunction reduces the pancreas’s ability to release insulin. People may be lean, have hearing loss, or have diabetes on their mother’s side of the family, and type 1 diabetes autoantibodies are usually absent. Insulin resistance can still occur, so the condition does not look exactly the same in every person.
Does mitochondrial diabetes usually run through the mother’s side of the family?
Mitochondrial diabetes is often inherited through the maternal line because mitochondrial DNA is passed from mothers to their children. A common associated change is m.3243A>G, but it is not the only cause, and a lack of maternal family history does not rule out the condition.
Can I take metformin if I have mitochondrial diabetes or Fanconi syndrome?
Metformin requires an individualized safety review in people with mitochondrial disease. The risk of lactic acidosis is especially important when kidney filtration is reduced or during acute kidney injury, low oxygen, severe infection, dehydration, or serious illness. Proximal tubular wasting with preserved kidney filtration is not automatically the same as poor metformin clearance, but you should review the medicine with your clinician and never stop or restart it on your own.
When might insulin be needed for mitochondrial diabetes?
Insulin may be needed when the pancreas no longer makes enough insulin to keep blood sugar controlled. A C-peptide test can help show how much insulin your pancreas is still producing, but the decision also depends on your glucose results, symptoms, and overall health. Your diabetes clinician can determine when insulin is appropriate.
How often should I have my hearing checked with mitochondrial diabetes?
Hearing loss is common in some people with mitochondrial diabetes and may appear before or after the diabetes diagnosis. Regular hearing evaluations, often annually, can help identify changes early and guide supportive care.
What should my sick-day plan include if I have mitochondrial diabetes?
Your clinician should give you individualized instructions for glucose checks, insulin or other medicines, hydration, and when to check ketones during illness. A clear plan is important because illness can place extra stress on mitochondria and dehydration can increase medication-related risks.

Get notified when new evidence is published on Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Toward Understanding the Molecular Basis and Precise Diagnosis of Mitochondrial Diabetes: A Comprehensive Review.

    Skoczylas S, Banach K, Zmysłowska A

    The Yale journal of biology and medicine 2026; (99(3)):466-487 doi:10.59249/GBKY6240.

    PMID: 43005028
  2. 2

    THE ROLE OF HETEROPLASMY IN THE DIAGNOSIS AND MANAGEMENT OF MATERNALLY INHERITED DIABETES AND DEAFNESS.

    Robinson KN, Terrazas S, Giordano-Mooga S, Xavier NA

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(2)):241-246 doi:10.4158/EP-2019-0270.

    PMID: 31682520
  3. 3

    MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.

    El-Hattab AW, Adesina AM, Jones J, Scaglia F

    Molecular genetics and metabolism 2015; (116(1-2)):4-12.

    PMID: 26095523
  4. 4

    The Mutations and Clinical Variability in Maternally Inherited Diabetes and Deafness: An Analysis of 161 Patients.

    Yang M, Xu L, Xu C, et al.

    Frontiers in endocrinology 2021; (12()):728043 doi:10.3389/fendo.2021.728043.

    PMID: 34899594
  5. 5

    Prevalence and treatment of mitochondrial diabetes in Southwest Finland.

    Rindell N, Immonen H, Martikainen MH

    Journal of diabetes and metabolic disorders 2026; (25(1)):154 doi:10.1007/s40200-026-01964-x.

    PMID: 42255315
  6. 6

    Approach to the Patient: Mitochondrial Diabetes: Contemporary Cases and a Precision Medicine Approach.

    Oppenheimer KR, Himelhoch NT, McCullough ME, et al.

    The Journal of clinical endocrinology and metabolism 2026; (111(4)):1175-1186 doi:10.1210/clinem/dgaf698.

    PMID: 41472381
  7. 7

    Is Type 2 Diabetes a Primary Mitochondrial Disorder?

    Weksler-Zangen S

    Cells 2022; (11(10)) doi:10.3390/cells11101617.

    PMID: 35626654
  8. 8

    Mitochondrial disease: an uncommon but important cause of diabetes mellitus

    Yee ML, Wong R, Datta M, et al.

    Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-18-0091.

    PMID: 30306776
  9. 9

    Metformin-associated lactic acidosis: Current perspectives on causes and risk.

    DeFronzo R, Fleming GA, Chen K, Bicsak TA

    Metabolism: clinical and experimental 2016; (65(2)):20-9.

    PMID: 26773926
  10. 10

    Mitochondrial heteroplasmy-phenotype correlation and response to glucose lowering therapy in subjects with m.3243A>G mutations.

    Ng N, Sanchez-Lechuga B, McCarrick CJ, et al.

    Diabetes & metabolism 2025; (51(5)):101678 doi:10.1016/j.diabet.2025.101678.

    PMID: 40541739
  11. 11

    Precision treatment of beta-cell monogenic diabetes: a systematic review.

    Naylor RN, Patel KA, Kettunen JLT, et al.

    Communications medicine 2024; (4(1)):145 doi:10.1038/s43856-024-00556-1.

    PMID: 39025920
  12. 12

    Glucagon-Like Peptide-1 Receptor Agonists in the Management of Mitochondrial Diabetes in an Adolescent: A Case Report.

    Hayes E, Nillsen A, Rowe PW, et al.

    Hormone research in paediatrics 2026; 1-9 doi:10.1159/000552014.

    PMID: 41999618
  13. 13

    Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?

    Borner T, Tinsley IC, Doyle RP, et al.

    British journal of pharmacology 2022; (179(4)):542-556 doi:10.1111/bph.15647.

    PMID: 34363224
  14. 14

    Assessing glycaemic impact of FreeStyle libre monitoring in patients with insulin-treated type 2 diabetes: a retrospective real-world analysis.

    Atkinson M, Williams DM, Crockett E, et al.

    Journal of diabetes and metabolic disorders 2025; (24(1)):72 doi:10.1007/s40200-025-01572-1.

    PMID: 40041676
  15. 15

    Early Onset of Diabetes Mellitus Accelerates Cognitive Decline in Japanese Patients with Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes.

    Murakami T, Shinoto Y, Yonemitsu S, et al.

    The Tohoku journal of experimental medicine 2016; (238(4)):311-6 doi:10.1620/tjem.238.311.

    PMID: 27063563
  16. 16

    Case report: mitochondrial diabetes mellitus in a Chinese family due to m.3243A>G.

    Bai W, Zhang Q, Fan Y, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(8)):777-781 doi:10.1515/jpem-2023-0016.

    PMID: 37459161
  17. 17

    Comprehensive Phenotype and Treatment Description of Mitochondrial Diabetes: Insights From a Large Cohort Study.

    Plaza Enriquez L, Ibrahim R, Ayari L, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(6)):909-915 doi:10.1016/j.eprac.2026.01.010.

    PMID: 41621650
  18. 18

    Co-prescription of metformin and glucagon-like peptide-1 receptor agonists and metformin-associated lactic acidosis: A case series.

    Hussain H, Ali M, Lorlowhakarn K, et al.

    Clinical nephrology. Case studies 2026; (14()):39-45 doi:10.5414/CNCS111965.

    PMID: 42164410

This page is for informational purposes only and does not constitute medical advice. Ask your endocrinology team before changing metformin, insulin, or any other treatment, especially if you have Fanconi syndrome or become ill.